LABCORP HOLDINGS INC. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
LABCORP HOLDINGS INC. (LH) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of $877.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-02-24
- LABCORP HOLDINGS INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2024-12-31 was $143.60M.
- LABCORP HOLDINGS INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2024-09-30 was $169.60M, a 7.63% decline year-over-year.
- LABCORP HOLDINGS INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2024-06-30 was $205.60M, a 32.47% increase year-over-year.
- LABCORP HOLDINGS INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2024-03-31 was $228.30M, a 9.55% increase year-over-year.
- LABCORP HOLDINGS INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2025 was $877.70M, a 17.48% increase from fiscal 2024.
- LABCORP HOLDINGS INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2024 was $747.10M, a 96.40% increase from fiscal 2023.
- LABCORP HOLDINGS INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2023 was $380.40M, a 62.09% decline from fiscal 2022.
- LABCORP HOLDINGS INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2022 was $1.00B, a 54.34% decline from fiscal 2021.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2025-12-31 | $877.70M 10-K · filed 2026-02-24 | |||
| 2024-12-31 | $143.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $313.20M derived: sum of 2 quarters · filed 2026-02-24 | $518.80M derived: sum of 3 quarters · filed 2026-02-24 | $747.10M 10-K · filed 2026-02-24 |
| 2024-09-30 | $169.60M 10-Q · filed 2024-10-29 | $375.20M derived: sum of 2 quarters · filed 2024-10-29 | $603.50M 10-Q · filed 2024-10-29 | $436.70M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $205.60M 10-Q · filed 2024-08-02 | $433.90M 10-Q · filed 2024-08-02 | $267.10M derived: sum of 3 quarters · filed 2026-02-24 | $450.70M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $228.30M 10-Q · filed 2024-04-30 | $61.50M derived: sum of 2 quarters · filed 2026-02-24 | $245.10M derived: sum of 3 quarters · filed 2026-02-24 | $400.30M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | -$166.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $16.80M derived: sum of 2 quarters · filed 2026-02-24 | $172.00M derived: sum of 3 quarters · filed 2026-02-24 | $380.40M 10-K · filed 2026-02-24 |
| 2023-09-30 | $183.60M 10-Q · filed 2024-10-29 | $338.80M derived: sum of 2 quarters · filed 2024-10-29 | $547.20M 10-Q · filed 2024-10-29 | $584.30M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $155.20M 10-Q · filed 2024-08-02 | $363.60M 10-Q · filed 2024-08-02 | $400.70M derived: sum of 3 quarters · filed 2025-02-25 | $678.00M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $208.40M 10-Q · filed 2024-04-30 | $245.50M derived: sum of 2 quarters · filed 2025-02-25 | $522.80M derived: sum of 3 quarters · filed 2025-02-25 | $790.80M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $37.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $314.40M derived: sum of 2 quarters · filed 2025-02-25 | $582.40M derived: sum of 3 quarters · filed 2025-02-25 | $1.00B 10-K · filed 2025-02-25 |
| 2022-09-30 | $277.30M 10-Q · filed 2023-10-30 | $545.30M derived: sum of 2 quarters · filed 2023-10-30 | $966.40M 10-Q · filed 2023-10-30 | |
| 2022-06-30 | $268.00M 10-Q · filed 2023-08-04 | $689.10M 10-Q · filed 2023-08-04 | ||
| 2021-12-31 | $2.20B 10-K · filed 2024-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| QUEST DIAGNOSTICS INC (DGX) | United States | $26.096B | 22.09 |
| Guardant Health, Inc. (GH) | United States | $23.675B | -12.65 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |